Ad26.COV2.S breakthrough infections induce high titers of neutralizing antibodies against Omicron and other SARS-CoV-2 variants of concern

Show simple item record

dc.contributor.author Kitchin, Dale
dc.contributor.author Richardson, Simone I.
dc.contributor.author Van der Mescht, Mieke Adri
dc.contributor.author Motlou, Thopisang
dc.contributor.author Mzindle, Nonkululeko
dc.contributor.author Moyo-Gwete, Thandeka
dc.contributor.author Makhado, Zanele
dc.contributor.author Ayres, Frances
dc.contributor.author Manamela, Nelia P.
dc.contributor.author Spencer, Holly
dc.contributor.author Lambson, Bronwen
dc.contributor.author Oosthuysen, Brent
dc.contributor.author Kaldine, Haajira
dc.contributor.author Du Pisanie, Marizane
dc.contributor.author Mennen, Mathilda
dc.contributor.author Skelem, Sango
dc.contributor.author Williams, Noleen
dc.contributor.author Ntusi, Ntobeko A.B.
dc.contributor.author Burgers, Wendy A.
dc.contributor.author Gray, Glenda G.
dc.contributor.author Bekker, Linda-Gail
dc.contributor.author Boswell, Michael T.
dc.contributor.author Rossouw, Theresa M.
dc.contributor.author Ueckermann, Veronica
dc.contributor.author Moore, Penny L.
dc.date.accessioned 2023-05-10T12:08:52Z
dc.date.available 2023-05-10T12:08:52Z
dc.date.issued 2022-03-15
dc.description.abstract The Janssen (Johnson & Johnson) Ad26.COV2.S non-replicating viral vector vaccine has been widely deployed for COVID-19 vaccination programs in resource-limited settings. Here we confirm that neutralizing and binding antibody responses to Ad26.COV2.S vaccination are stable for 6 months post-vaccination, when tested against multiple SARS-CoV-2 variants. Secondly, using longitudinal samples from individuals who experienced clinically mild breakthrough infections 4 to 5 months after vaccination, we show dramatically boosted binding antibodies, Fc effector function, and neutralization. These high titer responses are of similar magnitude to humoral immune responses measured in convalescent donors who had been hospitalized with severe illness, and are cross-reactive against diverse SARS-CoV-2 variants, including the neutralizationresistant Omicron (B.1.1.529) variant that currently dominates global infections, as well as SARS-CoV-1. These data have implications for population immunity in areas where the Ad26.COV2.S vaccine has been widely deployed, but where ongoing infections continue to occur at high levels. en_US
dc.description.department Immunology en_US
dc.description.department Internal Medicine en_US
dc.description.sponsorship The South African Medical Research Council, the South African Research Chairs Initiative of the Department of Science and Innovation; the National Research Foundation of South Africa, the EDCTP2 program of the European Union’s Horizon 2020 program, the Wellcome Centre for Infectious Diseases Research in Africa (CIDRI-Africa), which is supported by core funding from the Wellcome Trust and the Poliomyelitis Research Foundation, MRC UK, NRF, the Lily and Ernst Hausmann Trust and L’Oreal/Unesco Women in Science South Africa Young Talents awardee. en_US
dc.description.uri http://www.cell.com/cell-host-microbe/home en_US
dc.identifier.citation Kitchin, D., Richardson, S.I., Van der Mescht, M.A. et al. 2022, 'Ad26.COV2.S breakthrough infections induce high titers of neutralizing antibodies against Omicron and other SARS-CoV-2 variants of concern', Cell Host & Microbe, vol. 3, art. 100535, pp. 1-7, doi : 10.1016/j.xcrm.2022.100535. en_US
dc.identifier.issn 1931-3128 (print)
dc.identifier.issn 1934-6069 (online)
dc.identifier.other 10.1016/j.xcrm.2022.100535
dc.identifier.uri http://hdl.handle.net/2263/90615
dc.language.iso en en_US
dc.publisher Cell Press en_US
dc.rights © 2022 The Author(s). This is an open access article under the CC BY-NC-ND license. en_US
dc.subject Omicron (B.1.1.529) variant en_US
dc.subject Ad26.COV2.S en_US
dc.subject Vaccine en_US
dc.subject Infections en_US
dc.subject Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) en_US
dc.title Ad26.COV2.S breakthrough infections induce high titers of neutralizing antibodies against Omicron and other SARS-CoV-2 variants of concern en_US
dc.type Article en_US


Files in this item

This item appears in the following Collection(s)

Show simple item record